Substituted Cyclopentanes for Glaucoma Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for glaucoma, particularly primary open-angle glaucoma, often rely on topical β-adrenoreceptor antagonists, which may not effectively manage intraocular pressure, leading to potential vision loss, and there is a need for more effective ocular hypotensive agents.
Innovation Solution
Development of substituted cyclopentanes with prostaglandin activity, specifically compounds with certain structural formulas that can reduce intraocular pressure by facilitating aqueous humor outflow, delaying or preventing glaucoma progression and vision loss.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If topical β-adrenoreceptor antagonists are used for treating glaucoma, then treatment is provided for ocular hypertensive conditions, but the intraocular pressure reduction is insufficient leading to potential vision loss
Solution Approach 1:
The patent applies parameter changes by modifying the chemical structure of prostaglandin analogs through substitution patterns on the cyclopentane ring and side chains. This structural optimization enhances the pharmacological activity and intraocular pressure reducing efficacy compared to conventional β-adrenoreceptor antagonists, directly addressing the insufficiency of current treatments.
Solution Approach 2:
The invention creates composite molecular structures combining modified prostaglandin cores with specific substituted cyclopentane groups. These composite structures integrate multiple functional elements that work synergistically to achieve superior ocular hypotensive activity and overcome the limitations of single-mechanism therapies.
2Productivity
If conventional glaucoma treatments are used, then current standard therapy is maintained, but more effective ocular hypotensive agents are needed to prevent vision loss
Solution Approach 1:
The patent optimizes key molecular parameters including substituent positions, chain lengths, and functional group configurations on the prostaglandin scaffold. These parameter adjustments enhance receptor binding affinity and biological activity, producing compounds with improved efficacy for preventing vision loss in glaucoma patients.
Solution Approach 2:
The molecular structure is segmented into distinct functional regions: a modified cyclopentane core with specific substituents, intermediate linkers, and terminal functional groups. This segmentation allows independent optimization of each region's contribution to overall pharmacological activity and selective binding to ocular targets.
Data Source
AI summary
Disclosed herein are compounds having a formula:Therapeutic methods, medicaments, and compositions related thereto are also disclosed.